SCHEMBL17633644

SCHEMBL17633644

O=C1Nc2cccc(Cl)c2OC1c1ccc(C(F)(F)F)cc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PBRM1 Q86U86 2/20 0.40
TNKS O95271 1/20 0.39
MAPT P10636 2/20 0.39
KMT2A Q03164 2/20 0.39
MEN1 O00255 1/20 0.39
ALDH1A1 P00352 1/20 0.39
GAA P10253 1/20 0.39
BRD4 O60885 1/20 0.37
CA2 P00918 1/20 0.37
GSK3B P49841 1/20 0.35
PGR P06401 1/20 0.35
PARP1 P09874 1/20 0.34
PARP2 Q9UGN5 1/20 0.34
TP53 P04637 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
TRPM8 Q7Z2W7 3/20 0.34
CHRM5 P08912 1/20 0.33
CHRM3 P20309 1/20 0.33
C1R P00736 1/20 0.33
MCL1 Q07820 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17633643 0.86 MAPT (0.40) MAPTKMT2AMEN1ALDH1A1GAA
SCHEMBL17634295 0.85 MAPT (0.39) MAPTKMT2AMEN1ALDH1A1GAA
SCHEMBL17634084 0.79 PARP1 (0.49) MAPTKMT2AMEN1ALDH1A1GAA
SCHEMBL17634184 0.74 CA2 (0.37) KMT2AMEN1ALDH1A1BRD4CA2
SCHEMBL17633653 0.74 BRD4 (0.43) BRD4PGRTP53SMN1; SMN2
SCHEMBL17634206 0.74 BRD4 (0.51) KMT2ABRD4PGRTP53
SCHEMBL17633717 0.73 MEN1 (0.40) PBRM1TNKSMAPTKMT2AMEN1
SCHEMBL17633667 0.71 DAO (0.33) TNKSBRD4CA2PARP1
SCHEMBL31402319 0.70 PARP1 (0.56) KMT2AMEN1BRD4PARP1
SCHEMBL18128085 0.70 PARP1 (0.56) KMT2AMEN1BRD4PARP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3197900-B1 INHIBITORS OF HIF PROLYL HYDROXYLASE MERCK SHARP & DOHME (US) 2020-02-12 EP disclosed
US-9969752-B2 Inhibitors of HIF prolyl hydroxylase MERCK SHARP & DOHME CORP. (US) 2018-05-15 US disclosed
US-20170233412-A1 INHIBITORS OF HIF PROLYL HYDROXYLASE MERCK SHARP & DOHME CORP. (US) 2017-08-17 US disclosed
EP-3197900-A1 INHIBITORS OF HIF PROLYL HYDROXYLASE Merck Sharp & Dohme Corp. (US) 2017-08-02 EP disclosed
WO-2016049099-A1 INHIBITORS OF HIF PROLYL HYDROXYLASE MERCK SHARP & DOHME CORP. (US) 2016-03-31 WO disclosed
WO-2016045127-A1 INHIBITORS OF HIF PROLYL HYDROXYLASE MERCK SHARP & DOHME CORP. (US) 2016-03-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170233412-A1 INHIBITORS OF HIF PROLYL HYDROXYLASE HIF1AN, HIF1A, EGLN2 PBRM1 1452/4885TNKS 2628/4885MAPT 3798/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.